Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.65 |
| ▸ | F13A1 | P00488 | 11/20 | 0.65 |
| ▸ | TGM1 | P22735 | 8/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410584 | 0.85 | TGM2 (0.65) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL29060791 | 0.84 | TGM2 (0.64) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL1181084 | 0.84 | PKM (0.73) | TGM2F13A1TGM1PKM | |
| SCHEMBL27200534 | 0.84 | TGM2 (0.64) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL710366 | 0.84 | TGM2 (0.64) | TGM2F13A1TGM1PKM | |
| SCHEMBL3910274 | 0.84 | TGM2 (0.64) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL5253160 | 0.84 | POLB (0.70) | TGM2F13A1TGM1POLBSTS | |
| SCHEMBL1684972 | 0.84 | TGM2 (0.69) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL2252120 | 0.84 | TGM2 (0.63) | TGM2F13A1TGM1GPR119 | |
| SCHEMBL18153290 | 0.83 | PKM (0.66) | TGM2F13A1TGM1PKMSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163906-B2 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2148862-B1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | MAPK9, MAPK10, MAPK1 | TGM2 4435/4885F13A1 4462/4885TGM1 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.